Análisis farmacoeconómico de una estrategia de mantenimiento con lopinavir/ritonavir como monoterapia en pacientes con infección por el VIH

Escobar, Ismael; Pulido, Federico; Pérez, Esther; Arribas, José Ramón; García, María del Pilar; Hernando, Asunción.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 24(8): 490-494, oct. 2006. tab
Artículo en Es | IBECS (España) | ID: ibc-050893

Documentos relacionados

  1. Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
  2. Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients.
  3. Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies.
  4. Twice-Daily Dosing of Dolutegravir in Infants on Rifampicin Treatment: A Pharmacokinetic Substudy of the EMPIRICAL Trial.
  5. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
  6. Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir/ritonavir, in HIV-infected subjects, combined with clinical study and simulation results.
  7. Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency Virus.
  8. Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
  9. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
  10. Impact of fluctuation in frequency of human immunodeficiency virus/simian immunodeficiency virus reactivation during antiretroviral therapy interruption.